Advicenne Receives MHRA Approval to Market Sibnayal™ (ADV7103) in the UK for the Treatment of dRTA

by Admin_Advicenne | 2 Jul 2021

Advicenne Receives MHRA Approval to Market Sibnayal™ (ADV7103) in the UK for the Treatment of dRTA July 2, 2021 Paris, France, 2nd July 2021 – 7 am CEST – Advicenne (Euronext: ADVIC), a specialty pharmaceutical companydedicated to developing and commercializing...

Advicenne successfully raises circa €9.4m in a placement reserved to a category of persons

by Admin_Advicenne | 23 Jun 2021

Advicenne successfully raises circa €9.4m in a placement reserved to a category of persons 1 2 The following pages contain information regarding the share capital increase of Advicenne. For regulatory reasons, the distribution of the content of such information is...

Advicenne launches a reserved capital increase by means of an accelerated bookbuild offering for an amount of approx. EUR 10m

by Admin_Advicenne | 22 Jun 2021

Advicenne launches a reserved capital increase by means of an accelerated bookbuild offering for an amount of approx. EUR 10m 1 2 The following pages contain information regarding the share capital increase of Advicenne. For regulatory reasons, the distribution of the...

Advicenne provides an update on its activities following its Annual General Meeting

by Admin CP | 15 Jun 2021

Advicenne provides an update on its activities following its Annual General Meeting May 3, 2021 Paris, France, 3 May 2021 – 6 pm CEST – Advicenne (Euronext: ADVIC), a specialty pharmaceutical company dedicated to developing and commercializing innovative treatments...

Live Broadcast of the Annual General Meeting on June 14th, at 11:00 a.m

by Admin CP | 10 Jun 2021

Live Broadcast of the Annual General Meeting on June 14th, at 11:00 a.m May 3, 2021 Paris, France, 3 May 2021 – 6 pm CEST – Advicenne (Euronext: ADVIC), a specialty pharmaceutical company dedicated to developing and commercializing innovative treatments for those...